TG Therapeutics TGTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $461.9M+3.3% | $447.18M-0.1% | $447.47M+640% | $60.46M+54.4% | $39.15M+67.4% | ||
| $83K+40.7% | $59K+25.5% | $47K+14.6% | $41K-12.8% | $47K-30.9% | ||
| $69.65M+7.7% | $64.67M+6.1% | $60.97M+10.7% | $55.05M+14.3% | $48.17M+13.2% | ||
| —— | —— | —— | —— | —— | ||
| $1.2M-1.6% | $1.22M+0.1% | $1.22M-8.3% | $1.33M-20.2% | $1.66M-16.8% | ||
| $201.93M+14.4% | $176.44M+17.9% | $149.66M+1.2% | $147.91M+18.2% | $125.14M+60.2% | ||
| —— | —— | —— | —— | $76.23M+14.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$1.47M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.34M+550% | -$298K+18.6% | -$366K+57.5% | -$861K+18.2% | -$1.05M-39.7% | ||
| $1.87M+6.9% | $1.75M-3.6% | $1.81M-3.5% | $1.88M-3.4% | $1.95M+2.4% | ||
| —— | —— | —— | —— | -$3.46M+25.0% | ||
| -$1.98M+5.7% | -$2.1M+3.6% | -$2.18M+3.5% | -$2.26M+3.4% | -$2.34M+2.2% | ||
| $27.14M-36.0% | $42.43M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $240K+12.1% | $214K+27.4% | $168K+50.0% | $112K+60.0% | $70K+55.6% | ||
| $168.35M-29.1% | $237.5M-15.5% | $281.2M-4.9% | $295.75M-7.0% | $317.9M+2.3% | ||
| —— | —— | —— | —— | —— | ||
| $151.24M-31.9% | $222.24M-5.3% | $234.56M-23.0% | $304.61M-5.1% | $321.04M+3.4% | ||
| —— | —— | —— | —— | —— | ||
| $185.11M+103% | $91.24M-6.8% | $97.85M+350% | $21.76M+46.2% | $14.88M+69.9% | ||
| —— | —— | —— | —— | —— | ||
| $742K— | $0-100% | $453K0.0% | $453K+4,018% | $11K— | ||
| —— | —— | —— | —— | —— | ||
| $306.14M+437% | -$90.79M0.0% | -$90.79M-174% | $121.91M-5.1% | $128.49M-4.5% | ||
| $305.04M+388% | -$105.78M— | —— | —— | —— | ||
| $20.49M-15.5% | $24.25M-2.1% | $24.76M-3.9% | $25.77M+16.3% | $22.17M+20.0% | ||
| $11.32M+43.6% | $7.88M+4.6% | $7.53M+35.1% | $5.58M— | —— | ||
| $1.2M-1.6% | $1.22M+0.1% | $1.22M-8.3% | $1.33M-20.2% | $1.66M-16.8% | ||
| —— | —— | —— | —— | —— | ||
| -$1.98M+5.7% | -$2.1M+3.6% | -$2.18M+3.5% | -$2.26M+3.4% | -$2.34M+2.2% | ||
| $27.14M-36.0% | $42.43M— | —— | —— | —— | ||
| —— | —— | -$1.47M— | —— | —— | ||
| —— | $6.17M+33.3% | $4.63M+50.0% | $3.09M+100% | $1.54M— | ||
| $2.82M-25.6% | $3.79M-25.8% | $5.1M-16.8% | $6.13M-7.8% | $6.65M-4.8% | ||
| $1.87M+6.9% | $1.75M-3.6% | $1.81M-3.5% | $1.88M-3.4% | $1.95M+2.4% | ||
| —— | —— | —— | —— | —— | ||
| $151.24M-31.9% | $222.24M-5.3% | $234.56M-23.0% | $304.61M-5.1% | $321.04M+3.4% | ||
| $185.11M+103% | $91.24M-6.8% | $97.85M+350% | $21.76M+46.2% | $14.88M+69.9% | ||
| —— | —— | —— | —— | —— | ||
| $185K0.0% | $185K-3.6% | $192K-4.0% | $200K-3.4% | $207K-2.4% | ||
| —— | —— | —— | —— | -$552K-81.6% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | -$80.66M+25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $11.32M+43.6% | $7.88M+4.6% | $7.53M+35.1% | $5.58M— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does TG Therapeutics generate?
- TG Therapeutics (TGTX) generated -$95.4M in operating cash flow over the trailing twelve months.
- What is TG Therapeutics's free cash flow?
- After $240.0K of capital expenditures, TG Therapeutics's free cash flow was -$95.6M over the trailing twelve months, down 66.2% year over year.
- Where does TG Therapeutics's cash flow data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
